Tag:
Idenix Pharmaceuticals
Latest Headlines
Latest Headlines
Left on FDA 'hold,' Idenix hangs up on once-hot hep C drugs
For the past few weeks Idenix has been methodically moving away from its once-promising hepatitis C drugs, put on clinical hold by a jittery FDA in the wake of a catastrophic trial of a somewhat similar drug at Bristol-Myers Squibb.
Idenix moves out of FDA limbo with J&J hep C combo pact
Anxious to shake itself out of a painfully long regulatory limbo that has ensnared its top drug prospect, Idenix this morning announced that it has struck a deal to collaborate with J&J on another new hep C cocktail.
Idenix looks to Plan B as FDA hep C review plods on
Idenix, which had hoped to answer regulators' safety queries about IDX184 and IDX19368 and move on, says the FDA wants more time to study the drugs and the implications of the BMS-094 disaster before it makes a decision on the future of the two drugs.
Idenix plunges after FDA puts another hep C treatment on hold
Idenix already faces a partial clinical hold on its top hepatitis C program. Now the FDA has stepped in to add a clinical hold on its preclinical therapy IDX19368, another nucleotide polymerase inhibitor, or "nuc," in the pipeline.
UPDATED: Idenix craters as clinical hold spurs tox jitters for hot hep C drug
Idenix Pharmaceuticals went into free fall this morning, tumbling about 40% on the news that its nucleotide polymerase inhibitor IDX184 was put on partial clinical hold as the FDA studies whether a recent cardiac event that may well have spiked a similar treatment at Bristol-Myers Squibb raises similar toxicity issues for Idenix.
Idenix gets back Novartis' option on hot hep C work
Idenix and Novartis have agreed to terminate the pharma giant's option rights outlined in a 9-year-old licensing pact. Under a revised agreement, Novartis--which owns 31% of Idenix--will gain a royalty stream on approved hep C drug that comes out of the biotech.
Hep C drug deal frenzy can't be slowed by growing doubts
At the BIO CEO & Investor Conference in New York yesterday, Achillion CEO Michael Kishbauch wrapped up his remarks on the biotech's hepatitis C programs by making it clear that he was angling for
Idenix gets good news on hep C trial, but can't compete with Gilead
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis
JPM kicks off with fevered focus on the next big biotech deal
The news of the Bristol-Myers/Inhibitex deal couldn't have been better timed. With the biotech world converging on San Francisco today for the annual JP Morgan confab, there's nothing like a
Who's next on hep C biotech buyout hit list?
After the big biotech deal comes the big biotech buzz. And one of the big questions on everyone's mind after Gilead Sciences ( $GILD ) announced its $11 billion deal to acquire Pharmasset is, "Who's
